Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Multiple Cancer Types

This open-label, phase Ib / II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
Miscellaneous, Phase I
I/II
Das, Satya
NCT04579757
VICCPHI20125

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: